Ardsley Advisory Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Ardsley Advisory Partners’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-15,000	Closed	-$598K	–	171
2017 Q4	$598K	Buy	+15,000	New	+$593K	0.07%	90
2015 Q2	–	Sell	-981,300	Closed	-$11.9M	–	223
2015 Q1	$11.9M	Sell	981,300 -908,700	-48%	-$8.59M	1.65%	23
2014 Q4	$15.7M	Buy	1,890,000 +75,000	+4%	+$630K	2.49%	12
2014 Q3	$15.8M	Buy	1,815,000 +50,000	+3%	+$452K	2.08%	12
2014 Q2	$19.3M	Buy	1,765,000 +175,000	+11%	+$1.56M	2.46%	8
2014 Q1	$14.2M	Buy	1,590,000 +180,000	+13%	+$1.66M	2.13%	12
2013 Q4	$10.6M	Buy	+1,410,000	New	+$9.86M	1.41%	16

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Ardsley Advisory Partners's SUPN Position: Q1 2018 in Review

Ardsley Advisory Partners sold out of Supernus Pharmaceuticals (SUPN) in Q1 2018, closing a stake of 15,000 shares — an estimated $598K sold.

Ardsley Advisory Partners first reported a position in SUPN in Q4 2013 and held it in 7 quarters. The position peaked at $19.3M in Q2 2014. 312 funds tracked by Wall St. Rank hold SUPN as of Q1 2018.

Ardsley Advisory Partners reported no remaining Supernus Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Ardsley Advisory Partners sold 15,000 Supernus Pharmaceuticals shares in Q1 2018, an estimated $598K.
Ardsley Advisory Partners first reported a position in Supernus Pharmaceuticals in Q4 2013 and held it in 7 quarters.
Ardsley Advisory Partners's Supernus Pharmaceuticals position peaked at $19.3M in Q2 2014.
312 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2018.

Based on Ardsley Advisory Partners's 13F filing for Q1 2018, filed 15 May 2018.